Get started
Author

María Soledad Noya

Observed names: M. S. Noya-Pereira, M. Soledad Noya, Maria Soledad Noya, María-Soledad Noya, Soledad Noya
ORCID: 0009-0008-4875-3438
Observed ORCID: 0009-0008-4875-3438
OpenAlex ID: A5109336563
von Willebrand disease R1374C: Type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia)
2005 · Norma Penas, Almudena Pérez‐Rodríguez, et al. · American Journal of Hematology · 40
PDF
Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications
2016 · Marta Morado, Alex Freire Sandes, et al. · Cytometry Part B Clinical Cytometry · 36
PDF
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
2023 · Alberto Alvarez-Larrán, Beatriz Cuevas, et al. · HemaSphere · 25
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
2025 · Yan Beauverd, Jean-Christophe Ianotto, et al. · Leukemia · 22
Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera
2023 · Yan Beauverd, Jean-Christophe Ianotto, et al. · Blood · 18
Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes
2018 · Alberto Alvarez-Larran, Daniel Martínez, et al. · Journal of Clinical Pathology · 16
Cytoreductive treatment in patients with CALR ‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia
2020 · Alberto Alvarez‐Larrán, Anna Angona, et al. · British Journal of Haematology · 15
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
2024 · Marta Santaliestra, Marta Garrote, et al. · Leukemia · 6
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia
2020 · Ruth Stuckey, Luis-Felipe Casado, et al. · Journal of Molecular Diagnostics · 6
PDF
Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera
2026 · A. Angona, B. Cuevas, et al. · Blood Cancer Journal · 3
PDF
Excess Mortality in Polycythemia Vera and Essential Thrombocythemia
2018 · Arturo Pereira, Carlos Besses Raebel, et al. · Blood · 2
Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia
2024 · Marta Santaliestra, Marta Garrote, et al. · Blood · 1
Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia
2023 · Rodrigo Gil-Manso, Gonzalo Carreño, et al. · Blood · 1
PDF
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia
2026 · Gonzalo Carreño-Tarragona, Rodrigo Gil-Manso, et al. · Leukemia
PDF
Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line
2022 · Luis Felipe Casado Montero, Nuria Garcia-Ormeña, et al. · Blood
Prospective multi-center national study to standardize the follow-up of type 1 Gaucher disease patients treated with eliglustat under standard of care practice: TRAZELGA project
2019 · Marcio M. Andrade-Campos, Jorge J. Cebolla, et al. · Molecular Genetics and Metabolism
Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work
2018 · Ianotto Jean-Christophe, Jean-Jacques Kiladjian, et al. · Blood
Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project
2018 · Marcio M Andrade-Campos, Jorge J Cebolla, et al. · Blood
Multimorbidity in type 1 Gaucher disease patients under miglustat therapy
2018 · Blanca Medrano Engay, Ana Roy, et al. · Molecular Genetics and Metabolism
Health outcomes research study on patients with type 1 Gaucher disease under substrate reduction therapy (SRT)
2017 · Blanca Medrano Engay, Ana Roy, et al. · Molecular Genetics and Metabolism
Incidence of Malignancies in Gaucher's Disease Patients. Data of Spanish Gaucher's Disease Registry
2016 · Marcio Andrade-Campos, Abelardo Barez, et al. · Blood
Works count: 21
Citation count: 191
H-index: 7
I10-index: 7
Year
Topic
Type